Yacharter Yang
Psychiatric/Mental Health · Sacramento, CANPI 1548327190
Payments from drug & device makers
Across 254 payments — averaging $29.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$1K
- Teva Pharmaceuticals USA, Inc.$696
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$696
- Alkermes, Inc.$693
- Otsuka America Pharmaceutical, Inc.$662
- plus $2K from 11 others
What the payments were for
- Consulting fees$74010%
- Travel & lodging$1432%
- Food & beverage$6,25985%
- Education$2333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $1,483 |
| Johnson & Johnson | 41 | $1,138 |
| Teva Pharmaceuticals USA, Inc. | 29 | $696 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $696 |
| Alkermes, Inc. | 18 | $693 |
| Otsuka America Pharmaceutical, Inc. | 30 | $662 |
| Neurocrine Biosciences, Inc. | 27 | $654 |
| AbbVie | 17 | $355 |
| Lilly USA, LLC | 13 | $338 |
| Lundbeck LLC | 13 | $235 |
| Intra-sana Laboratories | 5 | $119 |
| Luye Pharma (USA) Ltd. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $83 |
| Indivior Inc. | 3 | $70 |
| Merck | 1 | $22 |
| Verity Pharmaceuticals Inc. | 1 | $22 |
| Pfizer | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$474
- UZEDY$253
- COBENFY$214
- VIVITROL$128
- INGREZZA$122
- INVEGA SUSTENNA$120
- ARISTADA INITIO$119
How this compares
$7,375 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 26 | $194,489 |
| Invega SustennaPaliperidone Palmitate | 43 | $122,701 |
| CaplytaLumateperone Tosylate | 16 | $27,161 |
| MounjaroTirzepatide | 18 | $17,184 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,347 |
| Lurasidone Hcl | 24 | $5,444 |
| Clozapine | 32 | $4,017 |
| Olanzapine | 158 | $3,493 |
| Olanzapine OdtOlanzapine | 26 | $2,442 |
| Divalproex Sodium ErDivalproex Sodium | 54 | $2,107 |
| Quetiapine Fumarate | 99 | $1,702 |
| Aripiprazole | 46 | $1,382 |
| Armour ThyroidThyroid,pork | 12 | $907 |
| Duloxetine Hcl | 45 | $835 |
| Trazodone Hcl | 121 | $822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $654 | $194,48926 claims |
| Johnson & JohnsonInvega Sustenna | $1,138 | $122,70143 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $696 | $27,16116 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $338 | $20,677176 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $83 | $7,34715 claims |
| AbbVieArmour Thyroid | $355 | $90712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Sacramento
- Joshua BurgettSacramento$239K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.